Fig. 1

Participant disposition. Summary of participant disposition of Latin American participants with type 2 diabetes mellitus who were treated with LM25 or IGL for 24 weeks. IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution